Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108
Provided By GlobeNewswire
Last update: Apr 9, 2025
Sustained positive preliminary data from all completed single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and food effects crossover, further supporting the safety and tolerability of PALI-2108
Read more at globenewswire.comNASDAQ:PALI (8/26/2025, 2:15:46 PM)
0.683
-0.01 (-1.04%)
Find more stocks in the Stock Screener
PALI Latest News and Analysis
